Viking Therapeutics, Inc. Aktie News

Viking Therapeutics, Inc. faces significant challenges with VK2735, lacking differentiation from established obesity treatments like ZEPBOUND and WEGOVY. Phase 2 data highlight tolerability issues at higher VK2735 doses, suggesting real-world efficacy may be limited by discontinuation rates. Viking's induction-maintenance strategy appears reactive, with competitors like Amgen and Pfizer advanci...

Conference Call Scheduled for Wednesday, February 11 at 4:30 p.m. Eastern Time  SAN DIEGO, Feb. 4, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the fourth quarter and year-...

The recent success of Novo Nordisk and Eli Lilly validates a potential $150 billion obesity drug market. Viking Therapeutics is a year or two from launching a drug that can compete with industry leaders.

Following recent challenges, these drugmakers could see solid clinical progress in the next 12 to 18 months. Both could launch products with significant sales potential and ride that wave through the medium term.

Eli Lilly and Viking Therapeutics both operate in the high-growth field of obesity drugs. This market is forecast to reach almost $100 billion by the end of the decade.

Shares of SoundHound AI have been all over the place of late, but that extreme volatility appears to have run its course. Viking Therapeutics wasn't the first name to the weight loss drug party.

Pfizer's deep pipeline could prove its greatest asset, helping it bounce back. Viking Therapeutics is developing a highly promising weight loss medicine.

Eli Lilly has skyrocketed due to its strength in the high-growth obesity drug market. One biotech company in particular may benefit from this market in just a few years.